These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. High risk myelodysplastic syndrome coexistent with chronic lymphocytic leukemia for more than 9 years: inhibition of the myeloid clone by the lymphoid clone? Bastion Y; Thomas X; Felman P; Campos L; Charrin C; Coiffier B Leukemia; 1991 Nov; 5(11):1006-9. PubMed ID: 1961029 [TBL] [Abstract][Full Text] [Related]
25. Retinoic acid in mono- or combined differentiation therapy of myelodysplasia and acute promyelocytic leukemia. Blazsek I; Farabos C; Musset M; Goldschmidt E; Comisso M; Benavides M; Wang ZY; Labat ML; Mathé G; Misset JL Biomed Pharmacother; 1991; 45(4-5):169-77. PubMed ID: 1932600 [TBL] [Abstract][Full Text] [Related]
28. Donor-cell myelodysplastic syndrome developing 13 years after marrow grafting for aplastic anemia. Haltrich I; Müller J; Szabó J; Kovács G; Kóos R; Poros A; Dobos M; Fekete G Cancer Genet Cytogenet; 2003 Apr; 142(2):124-8. PubMed ID: 12699888 [TBL] [Abstract][Full Text] [Related]
29. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753 [TBL] [Abstract][Full Text] [Related]
30. Modulation by retinoic acid of the growth of bone marrow cell progenitors from patients with myelodysplastic syndrome. De Francesco A; Sanavio F; Stacchini A; Piacibello W; Quaglino D; Aglietta M Haematologica; 1989; 74(1):25-8. PubMed ID: 2498179 [TBL] [Abstract][Full Text] [Related]
31. All-trans retinoic acid in the treatment of myelodysplastic syndromes. Visani G; Tosi P; Manfroi S; Ottaviani E; Finelli C; Cenacchi A; Bendandi M; Tura S Leuk Lymphoma; 1995 Oct; 19(3-4):277-80. PubMed ID: 8535219 [TBL] [Abstract][Full Text] [Related]
32. Effects of retinoids on in vitro differentiation of bone marrow cells in the myelodysplastic syndrome. Hast R; Beksac M; Axdorph S; Sjögren AM; Ost A; Reizenstein P Med Oncol Tumor Pharmacother; 1986; 3(1):35-8. PubMed ID: 3702509 [TBL] [Abstract][Full Text] [Related]
35. Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hemopoietic growth factors. Verhoef G; Van den Berghe H; Boogaerts M Leukemia; 1992 Aug; 6(8):766-9. PubMed ID: 1640727 [TBL] [Abstract][Full Text] [Related]
36. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid. Letendre L; Levitt R; Pierre RV; Schroeder G; Krook JA; Mailliard JE; Morton RF; Tschetter LK Am J Hematol; 1995 Apr; 48(4):233-6. PubMed ID: 7717370 [TBL] [Abstract][Full Text] [Related]
37. Extended cytogenetic follow-up of patients with myelodysplastic syndrome (MDS). White AD; Culligan DJ; Hoy TG; Jacobs A Br J Haematol; 1992 Aug; 81(4):499-502. PubMed ID: 1390235 [TBL] [Abstract][Full Text] [Related]
38. Trilineage response to granulocyte colony-stimulating factor administration in a patient with myelodysplastic syndrome. Perugini O; Montanari G; Nalli G Haematologica; 1995; 80(3):234-7. PubMed ID: 7545637 [TBL] [Abstract][Full Text] [Related]
39. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes. Venditti A; Tamburini A; Buccisano F; Scimò MT; Del Poeta G; Maurillo L; Cox MC; Abruzzese E; Tribalto M; Masi M; Amadori S Ann Hematol; 2000 Mar; 79(3):138-42. PubMed ID: 10803936 [TBL] [Abstract][Full Text] [Related]
40. Combined differentiating therapy for myelodysplastic syndromes: a phase II study. Ferrero D; Bruno B; Pregno P; Stefani S; Larizza E; Ciravegna G; Luraschi A; Vietti-Ramus G; Schinco P; Bazzan M; Gallo E; Pileri A Leuk Res; 1996 Oct; 20(10):867-76. PubMed ID: 8960111 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]